美国食品和药物管理局批准NervGen对慢性四肢的NVG-291进行第三期研究. FDA approves design for NervGen's Phase 3 study on NVG-291 for chronic tetraplegia.

纳尔夫基因制药公司宣布FDA已同意对NVG-291进行RESTORE第三期研究,该新药是慢性四肢的候选药物. NervGen Pharma has announced that the FDA has agreed to the design of the RESTORE Phase 3 study for NVG-291, a drug candidate for chronic tetraplegia. 这种调整使公司能够继续进行注册试验. This alignment allows the company to move forward with a registrational trial.